J. Rick Turner, PhD
Senior Director, Cardiovascular Safety
Dr. Rick Turner provides scientific leadership for cardiac safety programs and expert guidance to customers to help them design studies that will deliver in-depth data earlier in the process. His extensive knowledge of the most critical cardiovascular safety factors has gives customers strategic insight for their clinical development programs.
For over a decade, Dr. Turner has worked in the pharmaceutical arena, including positions as a clinical submissions scientist at GlaxoSmithKline, chairman of a department of clinical research at a school of pharmacy, and president and chief scientific officer at Turner Medical Communications LLC. He has published two books on drug development and one on drug safety. The latter book spans the continuum from in silico structure-activity simulations in the drug design phase to active post-marketing surveillance of adverse drug reactions once a marketed drug is widely prescribed.
In the field of cardiovascular behavioral medicine, Dr. Turner’s innovative behavioral genetic research investigated inherited and environmental influences in cardiovascular responses to psychological and behavioral stressors. He has published 50 peer-reviewed papers and five books in this field, and received two international research awards.
Dr. Turner has spoken before two FDA advisory committees on cardiovascular safety issues, given numerous presentations at international conferences and published several articles on topics within the field of integrated cardiac safety. He is currently a Visiting Fellow, Center for Medicine in the Public Interest.
